Amgen Q2 2022 Earnings Report
Key Takeaways
Amgen reported a 1% increase in total revenues to $6.6 billion for Q2 2022. GAAP EPS increased to $2.45, and non-GAAP EPS increased to $4.65. The company generated $1.7 billion in free cash flow.
Total revenues increased 1% to $6.6 billion, driven by growth in global product sales.
GAAP EPS increased to $2.45, and non-GAAP EPS increased to $4.65, driven by lower operating expenses.
Free cash flow remained consistent at $1.7 billion compared to Q2 2021.
2022 total revenues guidance revised to $25.5-$26.4 billion; EPS guidance revised to $11.01-$12.15 on a GAAP basis, and reaffirmed at $17.00-$18.00 on a non-GAAP basis.
Amgen
Amgen
Amgen Revenue by Segment
Amgen Revenue by Geographic Location
Forward Guidance
Amgen has revised its full year 2022 guidance, expecting total revenues to be in the range of $25.5 billion to $26.4 billion. GAAP EPS is projected to be between $11.01 and $12.15, while non-GAAP EPS is reaffirmed at $17.00 to $18.00.
Positive Outlook
- Total revenues are expected to be in the range of $25.5 billion to $26.4 billion.
- Capital expenditures are projected to be approximately $950 million.
- Share repurchases are expected to be in the range of $6.0 billion to $7.0 billion.
- GAAP EPS in the range of $11.01 to $12.15.
- Non-GAAP EPS reaffirmed at $17.00 to $18.00.
Challenges Ahead
- GAAP tax rate is expected to be in the range of 11.5% to 13.0%.
- Non-GAAP tax rate is expected to be in the range of 14.0% to 15.0%.
- Unspecified potential negative impacts from market competition.
- Unspecified potential negative impacts from pricing pressure.
- Unspecified potential negative impacts from reimbursement policies.
Revenue & Expenses
Visualization of income flow from segment revenue to net income